相似文献
1
Checkpoint inhibitors in AML: are we there yet?
Br J Haematol. 2020 Jan;188(1):159-167. doi: 10.1111/bjh.16358. Epub 2019 Dec 6.
2
Immune checkpoint inhibitors.
J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13.
3
Immunotherapy in hematologic malignancies: past, present, and future.
J Hematol Oncol. 2017 Apr 24;10(1):94. doi: 10.1186/s13045-017-0453-8.
4
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Curr Opin Hematol. 2018 Mar;25(2):136-145. doi: 10.1097/MOH.0000000000000401.
5
Targeting immune checkpoints in hematological malignancies.
J Hematol Oncol. 2020 Aug 12;13(1):111. doi: 10.1186/s13045-020-00947-6.
6
[The "immune checkpoints", how does it work].
Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1.
7
Checkpoint inhibitors in hematological malignancies.
J Hematol Oncol. 2017 May 8;10(1):103. doi: 10.1186/s13045-017-0474-3.
8
The next generation of immunotherapy: keeping lung cancer in check.
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
9
Biomarkers for checkpoint inhibition in hematologic malignancies.
Semin Cancer Biol. 2018 Oct;52(Pt 2):198-206. doi: 10.1016/j.semcancer.2018.05.005. Epub 2018 Jun 18.
10
Immunotherapy Toxicity.
Hematol Oncol Clin North Am. 2019 Apr;33(2):275-290. doi: 10.1016/j.hoc.2018.12.008. Epub 2019 Jan 28.
引用本文的文献
1
Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia.
Signal Transduct Target Ther. 2025 May 5;10(1):143. doi: 10.1038/s41392-025-02228-5.
2
Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis.
Heliyon. 2024 Oct 25;10(21):e39731. doi: 10.1016/j.heliyon.2024.e39731. eCollection 2024 Nov 15.
3
Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients.
Cancers (Basel). 2024 Jan 22;16(2):462. doi: 10.3390/cancers16020462.
4
Cancer vaccines in the clinic.
Bioeng Transl Med. 2023 Oct 27;9(1):e10588. doi: 10.1002/btm2.10588. eCollection 2024 Jan.
5
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Nat Commun. 2023 Oct 28;14(1):6895. doi: 10.1038/s41467-023-42585-9.
6
Single-cell transcriptomic profiling reveals immune cell heterogeneity in acute myeloid leukaemia peripheral blood mononuclear cells after chemotherapy.
Cell Oncol (Dordr). 2024 Feb;47(1):97-112. doi: 10.1007/s13402-023-00853-2. Epub 2023 Aug 24.
7
Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.
Cancers (Basel). 2023 Jun 30;15(13):3432. doi: 10.3390/cancers15133432.
8
Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies.
Chin J Cancer Res. 2023 Jun 30;35(3):245-251. doi: 10.21147/j.issn.1000-9604.2023.03.04.
9
Targeting the undruggable: menin inhibitors ante portas.
J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459. doi: 10.1007/s00432-023-04752-9. Epub 2023 Apr 27.
10
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.
Clin Cancer Res. 2023 May 15;29(10):1938-1951. doi: 10.1158/1078-0432.CCR-22-2601.
本文引用的文献
1
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.
2
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.
3
Hepatotoxicity of immune check point inhibitors: Approach and management.
Dig Liver Dis. 2019 Aug;51(8):1074-1078. doi: 10.1016/j.dld.2019.06.017. Epub 2019 Jul 8.
4
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.
Int J Cardiol. 2019 Oct 1;292:171-179. doi: 10.1016/j.ijcard.2019.05.028. Epub 2019 May 17.
5
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.
6
Immunotherapy of Melanoma: Facts and Hopes.
Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. doi: 10.1158/1078-0432.CCR-18-1550. Epub 2019 Mar 28.
7
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.
8
Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Emerg Med J. 2019 May;36(5):306-309. doi: 10.1136/emermed-2018-208091. Epub 2019 Mar 25.
9
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
10
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
Zotero 插件